'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Lyka Labs Limited
LYKALABS (NSE) · LYKALABS (BSE 500259) · ISIN INE933A01014 · Pharmaceuticals · Est. 1976 · listed 2000 · website
ESM Stage 2 · NSE ESM Stage 2 · BSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹42.31 cr and profit after tax ₹2.1 cr. Revenue was 45% higher than in Q1 FY26.
Next: Board meeting: financial results on 30 October 2026.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹42.31 cr | ₹2.1 cr | 0.58 | 10 Aug 2026 |
| Q4 FY26 standalone | ₹28.03 cr | −₹29.77 cr | −8.50 | 25 May 2026 |
| Q3 FY26 standalone | ₹30.73 cr | ₹0.28 cr | 0.08 | 29 Jan 2026 |
| Q2 FY26 standalone | ₹32.97 cr | −₹3.63 cr | −1.02 | 13 Nov 2025 |
| Q1 FY26 standalone | ₹29.18 cr | ₹0.81 cr | 0.22 | 1 Aug 2025 |
| Q4 FY25 standalone | ₹30.52 cr | ₹1.31 cr | 0.36 | 26 May 2025 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹87 cr | ₹48.36 cr | ₹170.75 cr |
| 30 Sep 2025 standalone | ₹132.13 cr | ₹30.78 cr | ₹195.29 cr |
| 31 Mar 2025 standalone | ₹134.94 cr | ₹37.93 cr | ₹205.58 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 58.45% | 0.15% | 0.66% | 41.55% |
Latest filings
- Annual Report FY2025-26 (New) 8 October 2026 · NSE
- Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 10 August 2026 · NSE
- As per the letter attached 10 August 2026 · BSE
- As per the letter attached 10 August 2026 · BSE
- Annual Report FY2025-26 (New) 17 July 2026 · BSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 8 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.